Document is current
Any future updates will be listed below
-
Authors
Gomes, Ana P. https://orcid.org/0000-0003-0881-727X
Ilter, Didem https://orcid.org/0000-0001-7506-8198
Low, Vivien https://orcid.org/0000-0002-8561-011X
Drapela, Stanislav
Schild, Tanya
Mullarky, Edouard
Han, Julie
Elia, Ilaria https://orcid.org/0000-0003-0922-9429
Broekaert, Dorien
Rosenzweig, Adam
Nagiec, Michal
Nunes, Joana B. https://orcid.org/0000-0002-8968-9670
Schaffer, Bethany E.
Mutvei, Anders P.
Asara, John M.
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Fendt, Sarah-Maria https://orcid.org/0000-0001-6018-9296
Blenis, John https://orcid.org/0000-0003-3622-2337
- License Information
-
More Information
Article History
Received: 4 January 2021
Accepted: 15 February 2022
First Online: 31 March 2022
Competing interests
: S.-M.F. has received funding from Bayer, Merck and Black Belt Therapeutics and has consulted for Fund<sup>+</sup>. L.C.C. owns equity in, receives compensation from and serves on the board of directors and scientific advisory board of Agios Pharmaceuticals and Petra Pharma Corporation. The other authors declare no competing interests.
